The team, Life Sciences Private Capital, plans to invest in early- to later-stage healthcare companies and seeks to capitalize on innovation in areas such as genetic medicine, autoimmune diseases, cardiometabolic diseases and rare disorders, according to a Nov. 1 press release from JPMorgan.
A group of advisers will assist the investment team, meeting regularly and providing guidance as needed to help portfolio companies. The advisers are:
- Laurie Glimcher, MD, president and CEO of the Boston-based Dana-Farber Cancer Institute
- Jeffrey Leiden, MD, PhD, executive chair and former CEO of drug developer Vertex Pharmaceuticals
- Frederic Moll, MD, a robotic surgery pioneer and entrepreneur who is now an executive at Johnson & Johnson
- Stephen Oesterle, MD, former senior vice president for medicine and technology at medical-technology company Medtronic
- Robert Stockman, co-founder and former CEO of medical device company REVA Medical
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
